IL-6/STAT3信号通路与肝癌研究进展  

Progress in research on IL-6/STAT3 signaling pathway and liver cancer

作　　者：柳辉 郭乐 丁淑琴[1] 李元[1] 姜中佳 LIU Hui;GUO Le;DING Shu-Qin;LI Yuan;JIANG Zhong-Jia(School of Clinical Medicine,Ningxia Medical University,Yinchuan 750004,China)

机构地区：[1]宁夏医科大学临床医学院,银川750004 [2]宁夏医科大学总医院宁夏临床病原微生物重点实验室,银川750004

出　　处：《中国免疫学杂志》2021年第13期1656-1662,共7页Chinese Journal of Immunology

基　　金：宁夏自然科学基金资助项目(2018AAC03074);宁夏回族自治区级大学生创新创业训练计划项目(S201910752035);宁夏医科大学校级项目(XT2017033);宁夏医科大学临床医学院一流学科开放课题项目(NXYLXK2017A05);宁夏青年科技人才托举工程项目(TJGC2018079);宁夏高等学校科学技术研究项目(NGY2018-75)。

摘　　要：IL-6是一种多效细胞因子,主要通过IL-6/STAT3信号通路发挥生物学效应。IL-6在肿瘤微环境中含量丰富,异常激活的IL-6/STAT3信号通路可通过影响肿瘤细胞增殖、迁移、侵袭、血管生成和凋亡等过程参与肝细胞癌(HCC)发生发展。靶向药物可通过阻断该信号通路显著抑制肝癌细胞恶性生物学行为,miRNAs可多靶点作用于IL-6/STAT3信号通路,抑制肝癌发生发展。深入了解IL-6/STAT3信号通路与HCC的关系有助于阐明其发病机制,并为HCC治疗提供新方向。IL-6 is a pleiotropic cytokine that exerts its biological effects mainly through IL-6/STAT3 signaling pathway.IL-6 is abundant in tumor microenvironment,and abnormally activated IL-6/STAT3 signaling pathway can participate in occurrence and development of hepatocellular carcinoma(HCC)via multiple processes affecting tumor cell proliferation,migration,invasion,angiogenesis and apoptosis.Targeting drugs can significantly inhibit malignant biological behavior of liver cancer cells by blocking this signal pathway.miRNAs can act on IL-6/STAT3 signaling pathway with multiple targets to inhibit occurrence and development of liver cancer.Understanding relationship between IL-6/STAT3 signaling pathway and HCC can help elucidate its pathogenesis and provide new directions for treatment.

关 键 词：IL-6 STAT3 IL-6/STAT3信号通路 肝细胞肝癌 

分 类 号：R735.7[医药卫生—肿瘤]